Lyell Immunopharma, Inc. (LYEL)
Last updated: 2026-10-21 10:25:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Summary
Lyell Immunopharma, Inc. (LYEL) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $9.70, with a market capitalization of $215.65M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $7.20 to $45.00. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$215.65M | |
$9.74 | |
$396.80 | |
$7.20 | |
$9.70 | |
-- | |
153.97K | |
-- | |
$45.00 | |
$7.20 | |
-- | |
-- |
Lyell Immunopharma, Inc. (LYEL) Pre-Market Stock Price
Lyell Immunopharma, Inc. (LYEL) is trading at $9.70 in pre-market trading as of 2026-10-21 08:11:00, up 0.01% ($0.00) from the previous close of $9.70
Pre-market trading shows how investors are pricing LYEL before the regular session opens. The current pre-market price is near the previous close, indicating positive early trading sentiment.
Lyell Immunopharma, Inc. (LYEL) 7-Day Stock Price Change
Over the past seven days, Lyell Immunopharma, Inc. (LYEL) moved from $8.27 to $9.70, representing a gain of 17.30% ($1.43).
The stock traded between $7.20 and $10.01 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 225.90 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
LYEL 52-Week Price Position
Position in Range: 6.6%
LYEL is currently trading at $9.70, placing it 6.6% of the way from its 52-week low of $7.20 to its 52-week high of $45.00. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Lyell Immunopharma, Inc. (LYEL)?
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
Lyell Immunopharma, Inc. Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 161 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Lyell Immunopharma, Inc. (LYEL) Stock on MEXC
Eligible investors can buy real shares of Lyell Immunopharma, Inc. (LYEL) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Lyell Immunopharma, Inc. (LYEL) stock price today?
2.Is LYEL stock going up or down today?
3.What is LYEL pre-market price?
4.What is LYEL after-hours price?
5.Is LYEL stock trading now?
6.Where does LYEL sit relative to its 52-week high and low?
7.What sector is Lyell Immunopharma, Inc. in?
8.What is Lyell Immunopharma, Inc.'s market capitalization and where is it listed?
9.How is LYEL valued in terms of P/E ratio and EPS?
10.Does Lyell Immunopharma, Inc. pay a dividend?
Explore More US Stocks
Search Stocks
LYEL Stock Calculator
Estimate the value between LYEL shares and USD.
LYEL Shares to USD
1.00 LYEL shares = 9.701 USD
Calculations are estimates based on the latest available price and are for reference only.



